CEE's RRRs Face Further Downward Revisions In Q312 Assessment

BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs) assessment. The major economic downgrades to CEE were priced into our RRRs in our Q212 assessment in January. However, there is little cause for optimism in our most recent assessment, with further downgrades in major markets (Poland, Greece and Turkey), as well as further downward revisions to Estonia, Lithuania, Kazakhstan, Croatia, Belarus and Uzbekistan. These revisions were a result of a combination of weaker drug market projections, resulting from austere drug policies and US dollar strength, which reduces our projections when measured in this global currency.

To read the full article, please choose one of the following options: